

SKYEPHARMA PLC  
Form 6-K  
March 03, 2006

**SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of March, 2006

SkyePharma PLC

---

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

---

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

---

**For Immediate Release**

**SkyePharma PLC**

**Clarification of Financial Position**

LONDON, UK, 3 March 2006 - SkyePharma PLC (LSE: SKP; Nasdaq: SKYE) wishes to clarify its financial position regarding the NAV group in the media today.

Under the UK Listing Rules a company is required to report if there is a material change in its financial position. There has been no material change in SkyePharma's financial condition since the working capital statement in the last financial statement.

Yesterday the NAV group issued a document and SkyePharma responded to all its claims proving that its financial governance are completely without foundation. However, verbally the NAV group has made outrageous claims in its position.

No mention of the alleged cash problem was included in the NAV group's written release. This is a tactical move by this small collection of shareholders are using which continue to destroy value in SkyePharma. The damage these slurs are causing.

Jerry Karabelas said:

"There is no cash problem.

"The behaviour of the NAV group is disgraceful. Having failed to make their innuendos over the years, they have spread rumours which are simply untrue.

"The time has come for other shareholders to stand up for SkyePharma before the NAV group do any more damage."

**For further information please contact:**

<b>SkyePharma PLC</b>	<b>+44 207 491 1777</b>
Frank Condella, Chief Executive Officer	
Peter Laing, Director of Corporate Communications	<b>+44 207 491 5124</b>
Sandra Haughton, US Investor Relations	<b>+1 212 753 5780</b>
<b>Buchanan Communications</b>	<b>+44 207 466 5000</b>
<b>Tim Anderson / Mark Court</b>	

**Notes for editors:**

**About SkyePharma**

SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery technologies and more effective drug formulations. There are now eleven approved products incorporating SkyePharma's oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities. For more information visit [www.skyepharma.com](http://www.skyepharma.com).

*Certain statements in this news release are forward-looking statements and are made in reliance upon the U.S. Private Securities Litigation Act of 1995. Although SkyePharma believes that the expectations expressed in these statements are reasonable, it can give no assurance that these expectations will materialize. Because of a number of risks and uncertainties, actual results may vary significantly from those expressed or implied in these statements. These risks include, but are not limited to, risks related to the development of new products, risks related to obtaining regulatory approval for existing, new or expanded indications of existing and new products, risks related to SkyePharma's ability to maintain or expand market share on a large scale or at all, risks related to SkyePharma's and its marketing partners' ability to maintain or expand market share in the face of changes in customer requirements, competition and regulatory compliance, the risk of product liability claims, risks related to the ownership of intellectual property, risks related to the ability to attract and retain key personnel, risks related to the ability to obtain financing, risks related to the ability to maintain adequate liquidity, risks related to the ability to maintain adequate insurance, risks related to the ability to maintain adequate compliance with applicable laws and regulations, risks related to the ability to maintain adequate compliance with applicable tax laws and regulations, risks related to the ability to maintain adequate compliance with applicable environmental laws and regulations, risks related to the ability to maintain adequate compliance with applicable data protection laws and regulations, risks related to the ability to maintain adequate compliance with applicable anti-corruption laws and regulations, risks related to the ability to maintain adequate compliance with applicable export control laws and regulations, risks related to the ability to maintain adequate compliance with applicable sanctions laws and regulations, risks related to the ability to maintain adequate compliance with applicable anti-bribe laws and regulations, risks related to the ability to maintain adequate compliance with applicable anti-trust laws and regulations, risks related to the ability to maintain adequate compliance with applicable competition laws and regulations, risks related to the ability to maintain adequate compliance with applicable consumer protection laws and regulations, risks related to the ability to maintain adequate compliance with applicable advertising laws and regulations, risks related to the ability to maintain adequate compliance with applicable intellectual property laws and regulations, risks related to the ability to maintain adequate compliance with applicable trademark laws and regulations, risks related to the ability to maintain adequate compliance with applicable patent laws and regulations, risks related to the ability to maintain adequate compliance with applicable copyright laws and regulations, risks related to the ability to maintain adequate compliance with applicable trade secret laws and regulations, risks related to the ability to maintain adequate compliance with applicable data protection laws and regulations, risks related to the ability to maintain adequate compliance with applicable privacy laws and regulations, risks related to the ability to maintain adequate compliance with applicable consumer protection laws and regulations, risks related to the ability to maintain adequate compliance with applicable advertising laws and regulations, risks related to the ability to maintain adequate compliance with applicable intellectual property laws and regulations, risks related to the ability to maintain adequate compliance with applicable trademark laws and regulations, risks related to the ability to maintain adequate compliance with applicable patent laws and regulations, risks related to the ability to maintain adequate compliance with applicable copyright laws and regulations, risks related to the ability to maintain adequate compliance with applicable trade secret laws and regulations.*

Edgar Filing: SKYEPHARMA PLC - Form 6-K

*risks related to SkyePharma's ability to manage growth. SkyePharma undertakes no obligation to make a forward-looking statement to reflect events or circumstances after the date of this release.*

END

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**SkyePharma PLC**

By: /s/ Douglas Parkhill

Name: Douglas Parkhill

Title: Company Secretary

Date: March 3, 2006